Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Strahlentherapie und Onkologie
Published in: Strahlentherapie und Onkologie 2/2017

01-02-2017 | Original Article

New quality assurance program integrating “modern radiotherapy” within the German Hodgkin Study Group

Authors: J. Kriz, C. Baues, R. Engenhart-Cabillic, U. Haverkamp, K. Herfarth, P. Lukas, H. Schmidberger, S. Marnitz-Schulze, M. Fuchs, A. Engert, Prof. Dr. H. T. Eich

Published in: Strahlentherapie und Onkologie | Issue 2/2017

Login to get access

Abstract

Introduction

Field design changed substantially from extended-field RT (EF-RT) to involved-field RT (IF-RT) and now to involved-node RT (IN-RT) and involved-site RT (IS-RT) as well as treatment techniques in radiotherapy (RT) of Hodgkin’s lymphoma (HL). The purpose of this article is to demonstrate the establishment of a quality assurance program (QAP) including modern RT techniques and field designs within the German Hodgkin Study Group (GHSG).

Methods

In the era of modern conformal RT, this QAP had to be fundamentally adapted and a new evaluation process has been intensively discussed by the radiotherapeutic expert panel of the GHSG.

Results

The expert panel developed guidelines and criteria to analyse “modern” field designs and treatment techniques. This work is based on a dataset of 11 patients treated within the sixth study generation (HD16–17).

Conclusion

To develop a QAP of “modern RT”, the expert panel defined criteria for analysing current RT procedures. The consensus of a modified QAP in ongoing and future trials is presented. With this schedule, the QAP of the GHSG could serve as a model for other study groups.
Literature
1.
Eich HT, Diehl V, Gorgen H, Pabst T, Markova J, Debus J et al (2010) Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol 28:4199–4206CrossRefPubMed
2.
Engert A, Plutschow A, Eich HT, Lohri A, Dorken B, Borchmann P et al (2010) Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med 363:640–652CrossRefPubMed
3.
Engert A, Haverkamp H, Kobe C, Markova J, Renner C, Ho A et al (2012) Reduced intensity of chemotherapy and PET-giuded radiotherapy in patients with advanced stage Hodgkin lymphoma: an open-label, randomised phase 3 trial. Lancet 379:1791–1799CrossRefPubMed
4.
Engert A, Schiller P, Josting A et al (2003) Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with earlystage unfavorable Hodgkin’s lymphoma: results of the HD8 trial of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 21:3601–3608CrossRefPubMed
5.
Girinsky T, van der Maazen R, Specht L et al (2006) Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol 79:270–277CrossRefPubMed
6.
Eich HT, Muller RP, Engenhart-Cabillic R et al (2008) Involved-node radiotherapy in early-stage Hodgkin’s lymphoma. Definition and guidelines of the German Hodgkin Study Group (GHSG). Strahlenther Onkol 184:406–410CrossRefPubMed
7.
Specht L, Yahalom J, Illidge T et al (2014) Modern radiotherapy for Hodgkin lymphoma – field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG). Int J Radiat Oncol Biol Phys 89(4):854–862CrossRefPubMed
8.
Kriz J, Spickermann M, Lehrich P et al (2015) Breath-hold technique in conventional APPA or intensity-modulated radiotherapy for Hodgkin’s lymphoma: comparison of ILROG IS-RT and the GHSG IF-RT. Strahlenther Onkol 191(9):717–725CrossRefPubMed
9.
Haverkamp U, Norkus D, Kriz J et al (2014) Optimization by visualization of indices. Strahlenther Onkol 190(11):1053–1059CrossRefPubMed
10.
Müller RP, Eich HT (2005) The development of quality assurance programs for radiotherapy within the German Hodgkin Study Group (GHSG). Introduction, continuing work, and results of the radiotherapy reference panel. Strahlenther Onkol 181(9):557–566CrossRefPubMed
11.
Duhmke E, Diehl V, Loeffler M et al (1996) Randomized trial with early-stage Hodgkin’s disease testing 30 Gy vs. 40 Gy extended field radiotherapy alone. Int J Radiat Oncol Biol Phys 36:305–310CrossRefPubMed
12.
Eich HT, Engenhart-Cabillic R, Hansemann K et al (2008) Quality control of involved field radiotherapy in patients with early-favorable (HD10) and early-unfavorable (HD11) Hodgkin’s lymphoma: an analysis of the German Hodgkin Study Group. Int J Radiat Oncol Biol Phys 71(5):1419–1424CrossRefPubMed
13.
Kriz J, Reinartz G, Dietlein M et al (2015) Relapse analysis of irradiated patients within the HD15 trial of the German Hodgkin Study Group. int J Radiat Oncol Biol Phys 92(1):46–53CrossRefPubMed
14.
ICRU Report No. 83 International Commission on Radiation Units and Measurements – Prescribing, Recording, and Reporting Intensity–Modulated Photon-Beam Therapy. ICRU 83; 2010.
15.
Chera BS, Rodriguez C, Morris CG et al (2009) Dosimetric comparison of three different involved nodal irradiation techniques for stage II Hodgkin’s lymphoma patients: conventional radiotherapy, intensity-modulated radiotherapy, and three-dimensional proton radiotherapy. Int J Radiat Oncol Biol Phys 75:1173–1180CrossRefPubMed
16.
Koeck J, Abo-Madyan Y, Lohr F et al (2012) Radiotherapy for early mediastinal Hodgkin lymphoma according to the German Hodgkin Study Group (GHSG): the roles of intensity-modulated radiotherapy and involved-node radiotherapy. Int J Radiat Oncol Biol Phys 83:268–276CrossRefPubMed
17.
Weber DC, Peguret N, Dipasquale G et al (2009) Involved-node and involved-field volumetric modulated arc vs. fixed beam intensity-modulated radiotherapy for female patients with early-stage supradiaphragmatic Hodgkin lymphoma: a comparative planning study. Int J Radiat Oncol Biol Phys 75:1578–1586CrossRefPubMed
Metadata
Title
New quality assurance program integrating “modern radiotherapy” within the German Hodgkin Study Group
Authors
J. Kriz
C. Baues
R. Engenhart-Cabillic
U. Haverkamp
K. Herfarth
P. Lukas
H. Schmidberger
S. Marnitz-Schulze
M. Fuchs
A. Engert
Prof. Dr. H. T. Eich
Publication date
01-02-2017
Publisher
Springer Berlin Heidelberg
Published in
Strahlentherapie und Onkologie / Issue 2/2017
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-016-1048-y

Other articles of this Issue 2/2017

Strahlentherapie und Onkologie 2/2017 Go to the issue

Case Study

Vertically transmitted HPV-dependent squamous cell carcinoma of the external auditory canal

Erratum

Erratum to: Fractionated vs. single-fraction stereotactic radiotherapy in patients with vestibular schwannoma

Original Article

Patient’s quality of life after high-dose radiation therapy for thoracic carcinomas

Editorial

Checkpoint inhibitors and radiation treatment in Hodgkin’s lymphoma

Original Article

Analysis of risk factors for pulmonary complications in patients with limited-stage small cell lung cancer

Original Article

Analyses of patterns-of-failure and prognostic factors according to radiation fields in early-stage Hodgkin lymphoma